Table 1.
Overview of cohorts used in this study.
| Subset | Number of patients | Induction duration | Clinical trial | Purpose |
|---|---|---|---|---|
| High-risk B-ALL | 156 | 4 weeks* | COG AALL0232 (NCT00075725) | Model training and testing |
| Training cohort | 109 | 4 weeks* | COG AALL0232 (NCT00075725) | Model training |
| Testing cohort | 47 | 4 weeks* | COG AALL0232 (NCT00075725) | Model testing |
| High risk B-ALL with induction failure | 3 | 6 weeks | COG AALL0232 (NCT00075725) to rescue therapy at physician’s discretion after failure | Validation |
| Standard-risk B-ALL | 174 | 4 weeks | COG AALL0331 (NCT00103285) | Validation |
* Patients with MRD > 1% at day 29 could receive up to 6 weeks of induction therapy